Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study by Tabernero, J et al.
ORIGINAL ARTICLE
Analysis of angiogenesis biomarkers for ramucirumab
efficacy in patients with metastatic colorectal cancer
from RAISE, a global, randomized, double-blind,
phase III study
J. Tabernero1,2*, R. R. Hozak3, T. Yoshino4, A. L. Cohn5, R. Obermannova6, G. Bodoky7,
R. Garcia-Carbonero8,9, T.-E. Ciuleanu10, D. C. Portnoy11, J. Prausová12, K. Muro13, R. W. Siegel14,
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Background: The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor
(VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved
overall survival (OS) and progression-free survival (PFS) compared with placeboþ FOLFIRI as second-line metastatic colorectal cancer
(mCRC) treatment. To identify patients who benefit the most from VEGFR-2 blockade, the RAISE trial design included a prospective
and comprehensive biomarker program that assessed the association of biomarkers with ramucirumab efficacy outcomes.
Patients and methods: Plasma and tumor tissue collection was mandatory. Overall, 1072 patients were randomized 1 : 1 to
the addition of ramucirumab or placebo to FOLFIRI chemotherapy. Patients were then randomized 1 : 2, for the biomarker
program, to marker exploratory (ME) and marker confirmatory (MC) groups. Analyses were carried out using exploratory assays
to assess the correlations of baseline marker levels [VEGF-C, VEGF-D, sVEGFR-1, sVEGFR-2, sVEGFR-3 (plasma), and VEGFR-2
(tumor tissue)] with clinical outcomes. Cox regression analyses were carried out for each candidate biomarker with stratification
factor adjustment.
Results: Biomarker results were available from>80% (n¼ 894) of patients. Analysis of the ME subset determined a VEGF-D level
of 115 pg/ml was appropriate for high/low subgroup analyses. Evaluation of the combined MEþMC populations found that
the median OS in the ramucirumabþ FOLFIRI arm compared with placeboþ FOLFIRI showed an improvement of 2.4 months in
the high VEGF-D subgroup [13.9 months (95% CI 12.5–15.6) versus 11.5 months (95% CI 10.1–12.4), respectively], and a decrease
of 0.5 month in the low VEGF-D subgroup [12.6 months (95% CI 10.7–14.0) versus 13.1 months (95% CI 11.8–17.0), respectively].
PFS results were consistent with OS. No trends were evident with the other antiangiogenic candidate biomarkers.
Conclusions: The RAISE biomarker program identified VEGF-D as a potential predictive biomarker for ramucirumab efficacy in
second-line mCRC. Development of an assay appropriate for testing in clinical practice is currently ongoing.
Clinical trials registration: NCT01183780.
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Introduction
Colorectal carcinoma (CRC) is the third leading type of cancer
and cause of cancer deaths worldwide [1, 2]. Metastatic CRC
(mCRC) develops in approximately half of the patients diagnosed
with CRC [3]. The poor prognosis of mCRC drives ongoing ef-
forts to find treatments that improve patients’ outcomes [4]. A
principal goal of translational research (TR) is the identification
of biomarkers to better select treatment options for patients. The
discovery of predictive biomarkers for drug efficacy, particularly
for antiangiogenic treatments, has been disappointing despite
huge efforts and investments. Therefore, selection of patients
more likely to benefit from antiangiogenic therapy has not yet
been possible, and, to date, no biomarker has been identified and
validated in mCRC to predict antiangiogenic treatment efficacy.
Ramucirumab is a human IgG1 monoclonal antibody that spe-
cifically binds to the extracellular domain of vascular endothelial
growth factor (VEGF) receptor (VEGFR)-2 with high affinity,
preventing binding of the agonist ligands VEGF-A, VEGF-C, and
VEGF-D and, consequently, VEGFR-2 activation [5].
The safety and efficacy of ramucirumab in combination with 5-
fluororuracil, leucovorin, and irinotecan (FOLFIRI) as second-line
therapy for patients with mCRC that progressed during or after first-
line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
were evaluated in a randomized, double-blind, placebo-controlled,
phase III trial (RAISE; NCT01183780) [6]. The RAISE trial demon-
strated a statistically significant survival benefit for patients treated
with ramucirumabþ FOLFIRI versus placeboþ FOLFIRI with a
median overall survival (OS) of 13.3 months for the ramucirumab
group versus 11.7 months for the placebo group [hazard ratio (HR)
0.84; 95% confidence interval (CI) 0.73–0.98; log-rank P¼ 0.0219].
The prespecified subgroup analyses did not identify any factors that
predicted ramucirumab efficacy, showing a consistent treatment ef-
fect for the analyzed variables [6, 7].
One of the planned study end points was to identify predictive
biomarkers for ramucirumab efficacy in second-line mCRC.
Investigations focused on angiogenesis-related mediators such as
VEGF family members and their receptors.
Methods
Study design
Details of the RAISE trial, including patient eligibility, trial design, ran-
domization, dose administration, clinical outcome definitions, and statis-
tical analyses, were published [6]. Briefly, eligible patients included those
with pathologically confirmed mCRC, known KRAS exon 2 mutation sta-
tus (mutant or wild-type); an Eastern Cooperative Oncology Group per-
formance status of 0 or 1; and disease progression during or within
6 months of the last dose of first-line combination therapy with bevacizu-
mab, oxaliplatin, and a fluoropyrimidine for metastatic disease. Patients
were randomized 1: 1 to receive on day 1 of each 2-week cycle either 8 mg/
kg ramucirumab or placebo as a 60-min intravenous infusion, followed by
the FOLFIRI regimen (180 mg/m2 irinotecan, 400 mg/m2 leucovorin, and
400 mg/m2 fluorouracil as a bolus, then 2400 mg/m2 as a 48-h infusion).
Sample collection and VEGF ligand and receptor
analysis
Plasma and tumor tissue collection was mandatory. Analyses were carried
out to assess the correlations of the baseline individual marker levels with
clinical outcomes. Plasma samples were collected from whole blood be-
fore cycle 1. VEGF-C, VEGF-D, soluble VEGFR-1 (sVEGFR-1), sVEGFR-
2, and sVEGFR-3 were assessed by exploratory, individual, proprietary
Eli Lilly and Company—developed dual-monoclonal sandwich im-
munoassays (Version 1 for each) [8]. Additional method details for the
VEGF-D assay are provided as supplementary material, available at
Annals of Oncology online. VEGF-A was not assessed because blood sam-
ples were collected in heparin tubes, and it has been determined that hep-
arin interferes with the bioanalytical assay for VEGF-A, such that reliable
results cannot be obtained. Archived tumor samples were submitted to
the central laboratory for VEGFR-2 immunohistochemistry assay [9]. A
semi-quantitative VEGFR-2 vascular H-score (range 0–300) was deter-
mined, based on the immunostaining intensity and the proportion of
vessel cells stained within the invasive tumor stroma. All assays were car-
ried out and scored while blinded to the study treatment and outcomes.
Statistical analysis
An adaptive analysis design [10] was used in which the population for the
study was randomly and prospectively split, after initial randomization,
into a marker exploratory (ME) set and a marker confirmatory (MC) set
in a 1 : 2 ratio. This approach allowed the broad exploration of markers
in the ME set of patients and then pre-specification for any noteworthy
findings to be confirmed independently in the MC set of patients.
Stratification was applied to balance the ME and MC sets according to
treatment assignment and the three study stratification factors: geo-
graphic region, KRAS exon 2 mutation status, and time to disease pro-
gression on the first-line treatment. Kaplan–Meier estimates and 95%
CIs were used to analyze OS and progression-free survival (PFS). Cox re-
gression analyses were carried out for each marker with stratification fac-
tors adjusted. A subpopulation treatment effect pattern plot (STEPP) was
used to evaluate the relationship of each marker’s levels with efficacy out-
comes. In generating the STEPP, the treatment effect was assessed in sub-
sets of patients who had similar biomarker levels, with the subsets
together spanning the full range of that marker’s values (known as a slid-
ing window approach).
Results
Biomarker results were available from>80% (n¼ 894) of pa-
tients. Median levels for markers are shown in supplementary
Table S1, available at Annals of Oncology online.
At the initial plasma ME subset analyses (ramucirumab,
n¼ 153; placebo, n¼ 146), VEGF-D showed a strong signal asso-
ciating higher levels with greater improvement in OS and PFS in
the ramucirumab arm (supplementary Figure S1, available at
Annals of Oncology online). To test the relationship of VEGF-D
levels with efficacy outcomes seen in the dataset from the ME pa-
tients, a VEGF-D level of 115 pg/ml was pre-specified (based on
multiple analyses from ME set) as the cut-off value for high and
low subgroup analysis of the independent MC population and
the full TR population (MEþMC populations). The flow of
VEGF-D patients is diagrammed in supplementary Figure S2,
available at Annals of Oncology online.
As shown in supplementary Table S2, available at Annals of
Oncology online, the results in the MC population independently
confirmed the ability of the pre-specified cutoff from the ME
dataset to predict ramucirumab efficacy (interaction P¼ 0.0107
and 0.0013 for OS and PFS, respectively). Here we present the full
TR population (MEþMC) analysis to provide the overall results
of the candidate biomarkers from the RAISE trial. The TR popu-
lation had similar demographics and baseline disease characteris-
tics compared with the intent-to-treat (ITT) population
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(supplementary Table S3, available at Annals of Oncology online).
Additionally, the OS stratified HR for the plasma TR population
was 0.89 (supplementary Figure S3A, available at Annals of
Oncology online), and the PFS stratified HR for the plasma TR
population was 0.80 (supplementary Figure S3B, available at
Annals of Oncology online). Altogether, these results indicate that
the overall plasma TR population is representative of the ITT
population.
The TR population was divided into subgroups of patients
with high VEGF-D plasma levels (115 pg/ml; n¼ 536), repre-
senting 61% of the TR population, and patients with low VEGF-
D levels (<115 pg/ml; n¼ 348), representing 39% of the TR
population. The demographics and baseline characteristics for
patients in the high and low VEGF-D groups are shown in
Table 1.
In the high VEGF-D group, ramucirumabþ FOLFIRI patients
(n¼ 270) had a median OS of 13.9 months (95% CI 12.5–15.6),
and placeboþ FOLFIRI patients (n¼ 266) had a median OS of
11.5 months (95% CI 10.1–12.4), with a stratified HR of 0.73 (95%
CI 0.60–0.89; P¼ 0.0022; Figure 1A). Ramucirumabþ FOLFIRI
patients had a median PFS of 6.0 months (95% CI 5.6–7.0), and
placeboþ FOLFIRI patients had a median PFS of 4.2 months
(95% CI 4.1–4.5), with a stratified HR of 0.62 (95% CI 0.52–0.74;
P< 0.0001; Figure 2A). In the low VEGF-D group,
ramucirumabþ FOLFIRI patients (n¼ 176) had a median OS of
12.6 months (95% CI 10.7–14.0), and placeboþ FOLFIRI patients
(n¼ 172) had a median OS of 13.1 months (95% CI 11.8–17.0),
with a stratified HR of 1.32 (95% CI 1.02–1.70; P¼ 0.0344;
Figure 1B). Ramucirumabþ FOLFIRI patients had a median PFS
of 5.4 months (95% CI 4.2–5.8), and placeboþ FOLFIRI patients
had a median PFS of 5.6 months (95% CI 5.3–6.9), with a stratified
HR of 1.16 (95% CI 0.93–1.45; P¼ 0.1930; Figure 2B). Interaction
analyses using the 115 pg/ml cut-off were statistically significant
for both OS and PFS (P¼ 0.0005 and P< 0.0001, respectively).
Table 1. Baseline patient characteristics by VEGF-D levels
VEGF-D High VEGF-D Low
Ramucirumab 1 FOLFIRI Placebo 1 FOLFIRI Ramucirumab 1 FOLFIRI Placebo 1 FOLFIRI
(N 5 270) (N 5 266) (N 5 176) (N 5 172)
n (%) n (%) n (%) n (%)
Age group
65 years 111 (41) 109 (41) 64 (36) 70 (41)
70 years 59 (22) 53 (20) 31 (18) 42 (24)
Gender
Male 137 (51) 162 (61) 100 (57) 110 (64)
Female 133 (49) 104 (39) 76 (43) 62 (36)
Geographic region
Japan/East Asia 67 (25) 61 (23) 33 (19) 28 (16)
Rest of world 203 (75) 205 (77) 143 (81) 144 (84)
Race
Black 8 (3) 9 (3) 6 (3) 5 (3)
Other 72 (27) 70 (26) 38 (22) 30 (17)
White 189 (70) 185 (70) 132 (75) 134 (78)
Missing 1 (<1) 2 (1) – 3 (2)
ECOG PS
0 143 (53) 126 (47) 88 (50) 93 (54)
1 127 (47) 140 (53) 87 (49) 79 (46)
Missing – – 1 (1) –
Time to progression after first-line
<6 months 63 (23) 71 (27) 43 (24) 36 (21)
6 months 207 (77) 195 (73) 133 (76) 136 (79)
KRAS status
Mutant 137 (51) 119 (45) 89 (51) 86 (50)
Wild type 133 (49) 147 (55) 87 (49) 86 (50)
CEA
>10 lg/l 179 (66) 178 (67) 126 (72) 111 (65)
10 lg/l 75 (28) 74 (28) 43 (24) 49 (28)
200 lg/l 51 (19) 59 (22) 43 (24) 28 (16)
<200 lg/l 203 (75) 193 (73) 126 (72) 132 (77)
Missing 16 (6) 14 (5) 7 (4) 12 (7)
CEA, carcinoembryonic antigen; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRI, 5-fluororuracil, leucovorin, and irinotecan;
VEGF-D, vascular endothelial growth factor D.
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The response rate for both VEGF-D groups (supplementary
Table S4, available at Annals of Oncology online) was roughly
similar to the ITT population [6].
In addition to the predictive relationship, VEGF-D was also
found to be prognostic, as indicated by the worse outcomes
within the placeboþ FOLFIRI group for patients with high
VEGF-D [median OS 11.5 months (95% CI 10.1–12.4)] com-
pared with patients with low VEGF-D [median OS 13.1 months
(95% CI 11.8–17.0); marker prognostic HR 1.42 (95% CI 1.1–
1.8); P¼ 0.0025].
To examine the VEGF-D predictive relationship more granu-
larly, STEPP figures were created. These figures show the point es-
timate for the treatment HR across a range of VEGF-D levels. For
both OS and PFS, a consistent relationship was observed between
HR and VEGF-D values (Figure 3A and B, respectively). These fig-
ures also demonstrate that the 115 pg/ml cut-off identified, based
on the results from the ME dataset, is well suited to the data from
the TR population. Examination of VEGF-D plasma levels by
tumor side revealed a similar distribution for VEGF-D levels
among patients in the left versus right subgroups (supplementary
Table S5, available at Annals of Oncology online). Additionally,
no correlation was found between VEGF-D and carcinoembryonic
antigen (CEA) levels (supplementary Table S6, available at
Annals of Oncology online). These results suggest that the greater
ramucirumab efficacy shown in patients with high VEGF-D levels
is independent of primary CRC tumor side and CEA baseline
values.
The relationships of OS and PFS results to levels of sVEGFR-1,
sVEGFR-2, sVEGFR-3, VEGF-C in plasma, and vascular
VEGFR-2 by immunohistochemistry in tumor are summarized
in supplementary Figures S4–S8, respectively. As with the results
from the ME set alone, no clear trends were evident for these
markers in the TR population.
Treatment-emergent adverse events (TEAEs) and adverse
events of special interest were analyzed by treatment arm and
VEGF-D level (Table 2). Most TEAEs that occurred more fre-
quently among ITT patients treated with ramucirumabþ
FOLFIRI (hypertension, thrombocytopenia, diarrhea, and fa-
tigue) [6] were elevated to a similar extent in both VEGF-D
groups. Grade3 neutropenia was higher in the high VEGF-D
ramucirumab group (42%) than in the low VEGF-D ramuciru-
mab group (32%; Table 2); however, febrile neutropenia events
were infrequent and had similar incidences in the high and low
VEGF-D groups. Adverse events of special interest (those associ-
ated with anti-VEGF therapies) showed a similar incidence across
the TR population (Table 2).
Figure 1. Overall survival in patients receiving ramucirumabþ FOLFIRI compared with that in patients receiving placeboþ FOLFIRI in pa-
tients with (A) high VEGF-D expression levels (115 pg/ml) and (B) low VEGF-D expression levels (<115 pg/ml). CI, confidence interval;
FOLFIRI, 5-fluororuracil, leucovorin, and irinotecan; HR, hazard ratio; VEGF-D, vascular endothelial growth factor D.
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Discussion
In the RAISE study, second-line treatment with ramucirumab in
combination with FOLFIRI demonstrated a statistically signifi-
cant survival benefit for mCRC patients when compared with
placeboþ FOLFIRI [6]. This report presents an evaluation of
VEGF ligands and receptors as predictive or prognostic markers
for ramucirumab efficacy. A consistent relationship was observed
for greater ramucirumab efficacy (both OS and PFS) in mCRC
patients with higher baseline plasma VEGF-D levels, with a me-
dian OS benefit from ramucirumab of 2.4 months. On the other
hand, in patients with low VEGF-D, the difference in median OS
was 15 days, favoring placebo. Similar differences were observed
for PFS. The other markers evaluated—sVEGFR-1, sVEGFR-2,
sVEGFR-3, VEGF-C, and vascular VEGFR-2 in tumor tissue—
did not demonstrate any clear trends.
Angiogenic factors play different roles in the angiogenesis
pathways. VEGF-A binding to VEGFR-2 is believed to be the key
signaling for the activation of the VEGF angiogenesis pathway.
However, other factors and receptors are also involved in the acti-
vation of the VEGF pathway, such as VEGF-C and VEGF-D bind-
ing to VEGFR-2 and VEGFR-3. Redundancy among family
members of angiogenic regulators has been established [11], and
it was hypothesized that related VEGF family members such as
VEGF-C and VEGF-D may continue to stimulate angiogenesis
despite inhibition by VEGF-A antibodies such as bevacizumab
[12, 13]. Published data associating the efficacy of antiangiogenic
therapy with VEGF-D levels in mCRC are scarce, but two publi-
cations analyzed that relationship in trials containing bevacizu-
mab. The first one, from the AGITG MAX trial, assessed the
relationship of angiogenic biomarker levels, assayed by immuno-
histochemistry in tumor tissue, with patients’ outcomes [14]. It
was a three-arm phase III study evaluating the effect on PFS of
adding bevacizumab with or without mitomycin to capecitabine
chemotherapy as first-line therapy for mCRC [14]. The AGITG
MAX analysis evaluated the predictive correlation between ex-
pression of angiogenesis-related factors (VEGF-A to VEGF-D,
VEGFR-1, and VEGFR-2 in tumor tissue) and outcomes of treat-
ments with or without bevacizumab [15]. Tumor specimens were
available for examination of VEGF and VEGFR expression from
57% of the study population (n¼ 268). Of the six biomarkers
analyzed, only VEGF-D served as a predictor of bevacizumab effi-
cacy on survival (OS and PFS). High expression of VEGF-D pre-
dicted resistance to bevacizumab plus chemotherapy, whereas
Figure 2. Progression-free survival in patients receiving ramucirumabþ FOLFIRI compared with that in patients receiving placeboþ FOLFIRI
in patients with (A) high VEGF-D expression levels (115 pg/ml) and (B) low VEGF-D expression levels (<115 pg/ml). CI, confidence interval;
FOLFIRI, 5-fluororuracil, leucovorin, and irinotecan; HR, hazard ratio; VEGF-D, vascular endothelial growth factor D.
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low expression of VEGF-D was associated with longer OS (HR
0.35; 95% CI 0.13–0.90) and PFS (HR 0.22; 95% CI 0.08–0.55) (P
interaction<0.05). The apparent higher benefit from bevacizu-
mab in patients with low VEGF-D is in contrast to the findings in
the RAISE trial, in which patients with higher levels of VEGF-D
derived more benefit with ramucirumab.
The second related publication was the biomarker analysis of
the Cancer and Leukemia Group B (CALGB)/Southwest
Oncology Group Trial 80405. The phase III CALGB study
(N¼ 1137) evaluated the efficacy and safety of adding bevacizu-
mab, cetuximab, or both to either FOLFOX or FOLFIRI as
first-line treatment of advanced CRC [11, 16]. In the biomarker
analysis, seven previously identified candidate biomarkers associ-
ated with outcomes for either bevacizumab or cetuximab were
assessed via multiplex enzyme-linked immunosorbent assay
(ELISA) systems [12]. Once again, VEGF-D associated with a sig-
nal. Lower plasma VEGF-D levels, analyzed by quartiles, were
associated with greater OS benefit from bevacizumab [HR 0.62
(95% CI 0.41–0.92) for the first quartile]. For the higher three
quartiles, no benefit from bevacizumab could be demonstrated
[HRs ranging from 1.02 (95% CI 0.71–1.47) to 1.34 (95% CI
0.91–1.97)]. A similar relationship was identified for PFS [11].
This analysis and that of the AGITG MAX trial [14] suggest that
bevacizumab seems to provide the greatest benefit to patients
with low circulating VEGF-D levels. One noteworthy comparison
between trials is that the baseline plasma levels of VEGF-D
measured in the CALGB trial were 10 times higher than those
measured in RAISE (median¼ 1.1 ng/ml for CALGB versus
Figure 3. VEGF-D (N¼ 884) subpopulation treatment effect pattern plot (STEPP) with sliding windows of size 200 with the largest overlap be-
tween windows of size 160 for (A) overall survival and (B) progression-free survival. VEGF-D, vascular endothelial growth factor D.
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0.135 ng/ml for RAISE), which raises a question regarding poten-
tial differences in assays used.
In patients with high levels of VEGF-D, the angiogenesis path-
way may be mainly activated by VEGF-D, which is not blocked
by VEGF-A binding antibodies such as bevacizumab. The high
VEGF-D levels could exist as an initial disease state or potentially
could arise as a mechanism of antiangiogenic resistance to thera-
peutic strategies that selectively block VEGF-A but not VEGF-D.
An increase in VEGF-D could thus serve as an angiogenic switch
from VEGF-A driving tumors to VEGF-D. Therefore, patients
with high VEGF-D levels who progressed after first-line therapy
containing bevacizumab, as in the RAISE study population, could
derive greater benefit from VEGFR-2 inhibition with ramuciru-
mab. The RAISE results suggest that ramucirumab-containing
treatment may compensate for the negative prognostic value
associated with high VEGF-D levels, yielding a difference in me-
dian OS of 2.4 months and similar outcomes to those seen with
low VEGF-D and a better prognosis.
Table 2. Treatment-emergent adverse events by VEGF-D cut point (115 pg/ml)
Any grade Grade 3

















(N 5176) (N 5271) (N 5172) (N 5265) (N 5176) (N 5271) (N 5172) (N 5265)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Any TEAEa 173 (98) 268 (99) 168 (98) 263 (99) 133 (76) 219 (81) 110 (64) 160 (60)
Diarrhea 106 (60) 163 (60) 100 (58) 130 (49) 18 (10) 33 (12) 21 (12) 22 (8)
Neutropenia 98 (56) 171 (63) 79 (46) 127 (48) 56 (32) 115 (42) 36 (21) 73 (28)
Fatigue 96 (55) 158 (58) 95 (55) 128 (48) 15 (9) 33 (12) 17 (10) 15 (6)
Nausea 91 (52) 138 (51) 90 (52) 136 (51) 5 (3) 6 (2) 3 (2) 9 (3)
Decreased appetite 65 (37) 114 (42) 47 (27) 73 (28) 3 (2) 9 (3) 3 (2) 2 (1)
Stomatitis 58 (33) 89 (33) 41 (24) 53 (20) 10 (6) 8 (3) 5 (3) 6 (2)
Constipation 57 (32) 72 (27) 44 (26) 56 (21) 0 4 (1) 4 (2) 3 (1)
Alopecia 55 (31) 78 (29) 67 (39) 79 (30) 0 0 0 0
Vomiting 54 (31) 80 (30) 52 (30) 70 (26) 5 (3) 8 (3) 3 (2) 9 (3)
Hypertension 49 (28) 71 (26) 19 (11) 20 (8) 22 (13) 28 (10) 8 (5) 4 (2)
Abdominal pain 49 (28) 69 (25) 38 (22) 72 (27) 7 (4) 9 (3) 7 (4) 8 (3)
Epistaxis 48 (27) 101 (37) 27 (16) 42 (16) 0 0 0 0
Thrombocytopenia 38 (22) 83 (31) 25 (15) 37 (14) 4 (2) 9 (3) 0 3 (1)
Peripheral edema 27 (15) 63 (23) 15 (9) 26 (10) 1 (<1) 0 0 0
Anemia 29 (16) 49 (18) 43 (25) 51 (19) 2 (1) 6 (2) 6 (3) 10 (4)
Adverse events of special interest
Hypertension 50 (28) 72 (27) 19 (11) 20 (8) 23 (13) 29 (11) 8 (5) 4 (2)
Venous thromboembolic events 16 (9) 21 (8) 14 (8) 12 (5) 10 (6) 10 (4) 4 (2) 3 (1)
Proteinuria 32 (18) 47 (17) 3 (2) 16 (6) 6 (3) 8 (3) 0 1 (<1)
Bleeding/hemorrhage event 65 (37) 130 (48) 38 (22) 60 (23) 3 (2) 9 (3) 4 (2) 3 (1)
GI perforation 3 (2) 5 (2) 0 3 (1) 3 (2) 5 (2) 0 3 (1)
Congestive heart failure 3 (2) 0 0 1 (<1) 3 (2) 0 0 1 (<1)
GI hemorrhage events 13 (7) 40 (15) 12 (7) 13 (5) 2 (1) 7 (3) 2 (1) 2 (1)
Infusion-related reaction 11 (6) 17 (6) 7 (4) 8 (3) 2 (1) 2 (1) 2 (1) 0
Renal failure 4 (2) 10 (4) 9 (5) 6 (2) 1 (1) 4 (1) 3 (2) 2 (1)
Arterial thromboembolic events 1 (1) 6 (2) 1 (1) 9 (3) 0 3 (1) 1 (1) 4 (2)
Healing complication 3 (2) 2 (<1) 1 (<1) 0 1 (<1) 0 0 0
Congestive heart failure 3 (2) 0 0 1 (<1) 3 (2) 0 0 1 (<1)
Fistula 2 (1) 1 (<1) 1 (<1) 0 0 0 0 0
Pulmonary hemorrhage events 1 (<1) 5 (2) 2 (1) 1 (<1) 0 0 0 0
Reversible posterior
leukoencephalopathy syndrome
0 1 (<1) 0 1 (<1) 0 0 0 0
Hepatic hemorrhage events 0 0 1 (<1) 0 0 0 1 (<1) 0
Terms in italics are consolidated terms. TEAEs graded by NCI-CTCAE v4.0.
aAll grades 20% or higher or grade3 5% or higher in either treatment arm.
FOLFIRI, 5-fluororuracil, leucovorin, and irinotecan; GI, gastrointestinal; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse
Events; PBO, placebo; RAM, ramucirumab; TEAE, treatment-emergent adverse event; VEGF-D, vascular endothelial growth factor D.
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In an unselected population, second-line ramucirumab treat-
ment could provide a remarkable benefit for those with high
VEGF-D levels, whereas the 15-day difference observed between
treatment arms for those with low VEGF-D is of questionable
clinical relevance. Overall, the risk-benefit ratio from the un-
selected ITT population continues to favor the use of
ramucirumab.
In conclusion, higher levels of VEGF-D expression are a poten-
tial predictive biomarker for ramucirumab efficacy (OS and
PFS). Despite the biologic plausibility of the association between
VEGF-D levels and patients’ outcomes in the RAISE trial, these
findings were obtained with an assay that was developed and vali-
dated for exploratory research purposes only. Development and
validation of an assay appropriate for clinical testing and decision
making are currently underway. If successful, this assay will be
used to confirm the relationship observed in the RAISE samples.
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